Study May Change Approach to Immunotherapy.
Researchers discovered that patients with a higher proportion of clonal neoantigens than subclonal neoantigens in their tumors are most likely to respond to immunotherapy. The findings may help guide the use of checkpoint inhibitors and lead to development of vaccines that stimulate the immune system to target specific neoantigens.